CKNTF — Cell Kinetics Share Price
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -74.65% | ||
| Return on Equity | -211.27% | ||
| Operating Margin | -11442.86% | ||
Financial Summary
| Year End 31st Dec | Unit | 2004 | 2005 | 2006 | 2007 | 2008 | 2009E | 2010E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | 0.02 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Cell Kinetics Limited is seeking to commercially exploit a growing need to study individual live cells, through the development, marketing and selling of an improved Cell carrier under the CKChip product line. The Cell Carrier can accommodate cells, each in individual wells, for measuring reactions of living cells while the cells are in a static state for a considerable period of time. The CKChip is a platform static cytometry technology that enables the simultaneous examination of many individual live cells using simple imaging methods such as fluorescence microscopy.
Directors
- Shmuel Peretz CHM (73)
- Asaf Ben-Arye CEO (51)
- Stephen Crea CAO (49)
- David Arie DRC (75)
- Mitchell Freeman DRC (63)
- Lauri Hanover DRC (55)
- Daniel Luchansky DRC (54)
- Jaclynn Shweky DRC (46)
- Last Annual
- December 31st, 2008
- Last Interim
- January 1st, 1970
- Incorporated
- May 23rd, 2002
- Public Since
- February 11th, 2008
- No. of Shareholders
- 98
- No. of Employees
- 10
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 19,999,961
- Address
- 2 Yodsat Street, LOD, 71291
- Web
- Phone
- +972 89182667
- Auditors
- Kost, Forer, Gabbay & Kasierer
Similar to CKNTF
Acorda Therapeutics
Pink Sheets on Nasdaq
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
FAQ
As of Today at 19:05 UTC, shares in Cell Kinetics are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in Cell Kinetics last closed at $0.00 and the price had moved by +9900% over the past 365 days. In terms of relative price strength the Cell Kinetics share price has outperformed the S&P500 Index by +8496.56% over the past year.
There is no consensus recommendation for this security.
Cell Kinetics does not currently pay a dividend.
Cell Kinetics does not currently pay a dividend.
Cell Kinetics does not currently pay a dividend.
To buy shares in Cell Kinetics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in Cell Kinetics had a market capitalisation of .
Here are the trading details for Cell Kinetics:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: CKNTF
Based on an overall assessment of its quality, value and momentum Cell Kinetics is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cell Kinetics. Over the past six months, its share price has outperformed the S&P500 Index by +766.77%.
As of the last closing price of $0.00, shares in Cell Kinetics were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Cell Kinetics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Cell Kinetics' management team is headed by:
- Shmuel Peretz - CHM
- Asaf Ben-Arye - CEO
- Stephen Crea - CAO
- David Arie - DRC
- Mitchell Freeman - DRC
- Lauri Hanover - DRC
- Daniel Luchansky - DRC
- Jaclynn Shweky - DRC